Skip to main content
PCI Biotech Holding logo

PCI Biotech Holding — Investor Relations & Filings

Ticker · PCIB ISIN · NO0010405640 LEI · 5967007LIEEXZXFIGG77 OL Manufacturing
Open in API
Filings indexed 752 across all filing types
Latest filing 2021-11-09 Regulatory Filings
Country NO Norway
Listing OL PCIB

About PCI Biotech Holding

https://www.pcibiotech.no/

PCI Biotech Holding is a biopharmaceutical company developing therapeutic products based on its proprietary Photochemical Internalization (PCI) technology. This platform is a drug and nucleic acid delivery system designed to enhance the intracellular delivery of therapeutic molecules. The company's development programs are focused on applications in immunotherapy, dermatology, and bioprocessing for the manufacturing of viral vectors. A primary therapeutic area for the technology is cancer, where it aims to improve the efficacy of novel and existing treatments.

Recent filings

Filing Released Lang Actions
PCI Biotech to present at the 9th International mRNA Health Conference
Regulatory Filings Classification · 100% confidence The document is a press release dated November 9, 2021, announcing that PCI Biotech will present a poster at the 9th International mRNA Health Conference. It details the presentation topic, the presenter (CSO), and mentions that the poster is enclosed ('Please find the poster enclosed'). This is not a full financial report (like 10-K or IR), nor is it a formal regulatory filing about share transactions or dividends. It is an announcement about participation in an industry event, which often falls under general investor relations or regulatory announcements. Since it is an announcement about presenting scientific/company information at a conference, and it is not a standard financial report, it best fits the general 'Regulatory Filings' (RNS) category as a miscellaneous corporate update, or potentially an Investor Presentation (IP) if the poster itself was the main focus, but the text is an announcement *of* the presentation, not the presentation itself. Given the context of a short press release announcing participation in a conference, RNS is the most appropriate fallback for non-standard corporate news.
2021-11-09 English
PCI Biotech: Presentation of fimaChem for bile duct cancer at IPA masterclass series
Regulatory Filings Classification · 99% confidence The document appears to be a presentation or summary of clinical trial data regarding a medical technique (Photochemical internalization - PCI) for treating Cholangiocarcinoma. It includes slides detailing study design (Phase I dose escalation), patient populations, safety results, survival data, and references to published scientific papers (Lancet Oncology, Endoscopy International Open). This content strongly aligns with scientific or clinical investigation findings presented to an audience, rather than a formal regulatory filing (like 10-K, AR, or ER). Given the structure (slides, figures, speaker disclosures) and the focus on clinical trial results and scientific literature, the most appropriate classification is Investor Presentation (IP), as these materials are frequently used to present detailed scientific/clinical progress to investors and analysts.
2021-11-08 English
PCI Biotech: Presentation of fimaChem for bile duct cancer at IPA masterclass series
Regulatory Filings Classification · 99% confidence The document is a short announcement (3558 characters) stating that a presentation regarding the fimaChem Phase I study results and the RELEASE study design will be given at an online event hosted by IPA today. Crucially, the text states, 'Please find the presentation enclosed.' This structure—a brief announcement about an event/report and the enclosure of the material—fits the definition of a Report Publication Announcement (RPA) rather than the full presentation itself (which would likely be classified as IP or ER if it contained financial results). Since it announces the publication/enclosure of presentation material, RPA is the most appropriate code based on Rule 2.
2021-11-08 English
PCI Biotech: Employee share option scheme
Director's Dealing Classification · 99% confidence The document text contains structured data fields typical of insider transaction reporting, specifically mentioning 'Primærinnsider' (Primary Insider), 'Etternavn' (Last Name), 'Fornavn' (First Name), 'Stilling / Rolle' (Position / Role - CEO), 'Transaksjonstype' (Transaction Type - Aksept av aksjeopsjon / Acceptance of stock option), ISIN code, and transaction details (Price, Volume, Date). This strongly indicates a report detailing personal share transactions by company directors or executives. This aligns perfectly with the definition for Director's Dealing (DIRS). The presence of 'CEO' and the nature of the transaction (stock option acceptance) confirms insider activity reporting.
2021-09-06 English
PCI Biotech: Employee share option scheme
Director's Dealing Classification · 95% confidence The document explicitly details the awarding of share options to key employees and primary insiders (CEO, CMO, CFO, etc.) under an authorization granted by the Annual General Meeting. This involves changes in executive compensation/incentives and reports on personal share transactions by directors/executives (insider trades). While it touches upon remuneration policy (DEF 14A) and insider transactions (DIRS), the core subject is the grant of options to management, which falls under Director's Dealing (DIRS) as it reports specific transactions/holdings of primary insiders, or potentially Remuneration Information (DEF 14A) if viewed as part of the compensation structure. Given the specific reporting of option allotments to named primary insiders and the reference to MAR Article 19 notifications (which mandate insider transaction reporting), Director's Dealing (DIRS) is the most precise fit for this type of disclosure regarding insider holdings changes via options. However, since the document is about the *grant* of options as part of an incentive scheme, and it mentions remuneration policy, it also strongly relates to compensation structure. Comparing DIRS (insider trades) vs DEF 14A (Remuneration Information): DEF 14A usually covers executive compensation tables. DIRS covers insider transactions. Since this is a direct report of insider option grants, DIRS is highly relevant. Let's re-evaluate the definitions. DIRS is for 'Report of personal share transactions by company directors and executives (insider trades)'. This is exactly what the latter half of the document does. DEF 14A is 'Report detailing compensation for top executives and directors'. The grant of options is a form of compensation. Given the context of reporting insider transactions under MAR 19, DIRS is a very strong candidate. If the document was purely about the overall compensation philosophy, DEF 14A would fit better. Since it reports specific grants to specific insiders, DIRS is chosen.
2021-09-06 English
Financial calendar
Report Publication Announcement Classification · 99% confidence The document is titled 'Financial calendar' and lists scheduled dates for future financial events like 'Half-yearly Report', 'Quarterly Report', 'Annual Report', and 'Annual General Meeting' for the years 2021 and 2022. It is not an actual report (like 10-K or IR) but rather an announcement detailing the schedule of future reports and meetings. Since there is no specific category for a 'Financial Calendar', and it is an announcement related to corporate events and reporting timelines, it best fits the general 'Regulatory Filings' (RNS) category as a miscellaneous corporate disclosure, or potentially a very high-level 'Report Publication Announcement' (RPA) if interpreted as announcing the schedule of publications. Given the content is purely a schedule and not an announcement of a specific report being published *now*, RNS is the most appropriate fallback for general corporate schedule disclosure.
2021-08-31 English

Browse filings by year

15 years

Report missing filing

Can't find a specific document? Let us know and we'll add it within 24 hours.

We will notify you once the filing is added.
Report sent
Thank you. We will check the data and update it shortly.